FDA nails Sun plant for same data deletions found at Ranbaxy

India's Sun Pharmaceutical intends to be the white knight that will turn around manufacturing problems at Ranbaxy Laboratories once it finalizes its $3.2 billion buyout of the troubled drugmaker. But a warning letter posted today by the FDA says employees at a now-banned Sun Pharmaceutical plant in India displayed the same kind of disregard for data testing that Ranbaxy has, deleting records of failed samples and then retesting products till it got the results it needed. Some batches that fell out of spec ended up being shipped to the U.S., while some test results were put in the trash, the FDA said. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.